Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of ...
South Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase 3 trial, but the company reckons it doesn’t spell the end of the programme.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback